Senti enters equity agreement for up to $4.55M financing
Senti Biosciences signed a commitment letter for up to $4.55M in convertible preferred stock, with quarterly funding obligations through Dec 2027, subject to specific conditions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed